Comparative Analysis of National Medical Academic Systems and the Chinese Medical Training Framework

Chapter 1: Introduction

Composition of the 1.1 Medical Academic System

The medical academic system is a comprehensive institutional framework that governs the production, dissemination, and application of medical knowledge within a country. It is not defined solely by prestigious universities or renowned journals; rather, it consists of multiple interlocking subsystems. To understand this system, one must first establish a "panoramic map" that positions scattered institutions, projects, and policy documents on a single canvas. This report deconstructs the medical academic system into six core dimensions. Subsequent analyses of individual countries and cross-national comparisons will be structured around these six dimensions to ensure consistency and facilitate effective horizontal comparison.

The first dimension is research funding, which answers "who pays and under what rules." Medical research involves high costs, long timelines, and significant risks, making it impossible to sustain through clinical revenue alone. It requires stable public or charitable funding. Funding agencies effectively determine which areas of research a nation prioritizes or neglects by setting budget sizes, defining project types, and establishing review criteria. The second dimension is the research institution, answering "where research happens." This includes medical schools and their affiliated hospitals, independent research institutes, teaching hospitals, and various clinical research networks. These entities dictate how research capabilities are organized and how clinical practice integrates with research in physical space.

The third dimension is academic publishing, addressing "how research findings are disseminated and circulated." This encompasses top-tier general medical journals, specialty journals, society publications, and emerging trends in Open Access (OA). Journals serve not only as vehicles for papers but also as gatekeepers for establishing priority and ensuring quality. The fourth dimension is academic evaluation, focusing on "the metrics used to assess scholars and institutions." This includes the quantity and quality of publications, competitive funding, peer review, quantitative tools such as the H-index, and institution-level assessments like the UK's Research Excellence Framework (REF). Evaluation criteria act as the "commanding stick" of the academic system; shifts in these criteria profoundly influence physicians' professional behaviors.

The fifth dimension is talent development, focusing on "how a young person evolves from a medical student into an independent physician-scientist." This encompasses degree structures, the integration of specialty training with research training, postdoctoral programs, and various talent initiatives. The seamless integration of clinical and research training tracks is a key indicator of the maturity of the medical academic system. The sixth dimension is research ethics and integrity, addressing "how to prevent misconduct and protect subjects." This includes ethics committee reviews, clinical trial registration, investigations into fabrication, falsification, and plagiarism, and governance of emerging forms of academic dishonesty such as "paper mills." These six dimensions are interconnected: funding shapes institutions, institutions cultivate talent, talent produces publications, publications undergo evaluation, and ethics and integrity permeate the entire process, serving as the foundation of the system.

The relationship between the 1.2 medical academic framework and clinical practice

Many frontline physicians mistakenly believe that the "academic system" belongs only to university professors and research institutes, having no relevance to daily outpatient or inpatient work. In reality, clinical practice and medical academia are not parallel tracks; they are two ends of the same endeavor. Every complex case, every suboptimal treatment outcome, and every issue where guidelines fall short encountered in clinical practice serves as a primary source for scientific inquiry. Conversely, evidence generated by the academic system returns to the bedside through clinical guidelines, treatment protocols, and drug labels, shaping the care plans for future patients. Physicians are not just users of medical evidence—they can also be its producers.

From the perspective of evidence flow, these elements form a closed loop: clinical practice raises questions, research design answers them, publication confirms results, peer review and systematic reviews filter reliable evidence, guidelines convert evidence into actionable recommendations, and finally, implementation in clinical settings validates the findings. Modern Evidence-Based Medicine (EBM) emphasizes high evidence levels from randomized controlled trials (RCTs) and systematic reviews because the academic community has developed methodologies to minimize bias and approach the truth. Understanding this system enables primary care physicians to interpret the evidence grades behind guidelines, grasp why some recommendations are "strong" while others are "weak," and maintain independent judgment amid complex information.

Conversely, when the academic system detaches from clinical practice, it breeds alienation where research is driven by publication pressure. Examples include prioritizing short-term lab metrics over real-world clinical outcomes, repeating low-value studies, and treating paper quantity as the sole objective. Whether through global reflections on "Publish or Perish" or China's reforms to de-emphasize publications, these efforts aim to realign academia with clinical reality. For frontline physicians, this means avoiding blind competition in paper counts. Instead, focus on your most familiar clinical settings to identify authentic, specific, and answerable questions—a direction that international medical research has increasingly embraced in recent years.

1.3 Analytical Framework and Scope

This report adopts an analytical framework of "unified dimensions, country-specific descriptions, cross-country comparisons, and practical implementation." First, each country is analyzed across six dimensions: funding systems, research entities, academic evaluation, journal publishing, talent development, and integrity/ethics, ensuring comparable narratives without misleading contrasts. Second, building on individual country profiles, Chapter 4 conducts a China–foreign comparison across eight thematic areas, summarizing key differences in tables where possible. Finally, Chapter 5 returns to the real-world scenarios of frontline physicians, offering actionable recommendations rather than merely describing institutional frameworks.

This report focuses on six representative medical research powerhouses: the United States, the United Kingdom, Germany, Japan, Australia, and the Netherlands. The U.S., anchored by the National Institutes of Health (NIH), represents the largest-scale sample in global biomedical research. The UK contributes REF assessments, clinical academic training pathways, and top-tier journals such as The Lancet. Germany exemplifies the European continental model with parallel university hospitals and national research institutions. Japan serves as a pioneer of modern medical systems in Asia. Australia stands out for its fund governance and philanthropic medical funding models. The Netherlands is renowned for high-quality clinical research conducted in a small country, supported by rigorous ethical registration systems. With varying scales and distinct approaches, these six nations offer valuable insights into the trade-offs of different institutional choices when compared to China's system.

Data Scope: The R&D investment intensity, institutional budgets, and funding rates covered in this report are primarily sourced from public data provided by national government agencies, the World Bank, the Organisation for Economic Co-operation and Development (OECD), and authoritative journals. Data retrieval was conducted as of November 2026. Due to variations in fiscal years across countries and budget adjustments driven by legislation, the report specifies the relevant year and scope for each cited figure. Where exact totals are unavailable, qualitative descriptions are provided rather than speculative estimates. For actual grant applications or research queries, please refer to the latest official information published on respective agency websites.

Chapter 2: Overview of National Medical Academic Systems by Country

2.1 U.S. Medical Academic System

2.1.1 Core Funding Agency: NIH's Operating Mechanisms and Program Framework

The National Institutes of Health (NIH) is the world's largest and most influential public biomedical research funding agency. Founded in 1887 as a single laboratory, it now comprises 27 Institutes and Centers (ICs), including the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID). Each IC maintains independent budgets and research priorities while operating under the coordination of the NIH Director's Office. With appropriations from the U.S. Congress, the NIH received approximately $47.36 billion in statutory funding for fiscal year 2024 and about $46.99 billion in project-level funding for fiscal year 2025, consistently ranking as the largest single biomedical funding organization globally.

NIH funds are primarily awarded to universities and research institutions across the U.S. and globally through competitive grants under its Extramural Program, with a smaller portion supporting intramural laboratories within NIH. The funding structure is organized by mechanism: R01 represents the classic investigator-initiated grant, serving as the "gold standard" for independent research capability; R21 supports exploratory, high-risk early-stage ideas; P-series grants fund large-scale collaborative projects involving multiple teams; K-series awards (e.g., K08, K23, K99) are career development awards for clinicians, helping them transition to independent investigators under mentorship; T32 supports institutional training programs; and F32 provides individual postdoctoral fellowships. Review follows a two-tier peer-review process: external experts on study sections evaluate applications first, followed by review from national advisory councils, with final funding decisions based on scores and budget availability. For example, in 2024, approximately 34,300 applications were received for R01-type grants, with 5,729 funded—an overall success rate of about 17%. Among applicants, roughly 20% were first-time applicants and 26% were senior researchers, highlighting the intense competition.

2.1.2 Research Entities: Medical Schools, Teaching Hospitals, and Independent Research Institutes

In the United States, academic medical centers (AMCs) are the primary entities driving medical research. Typically composed of medical schools, teaching hospitals, and multiple research institutes, AMCs include examples such as Harvard Medical School with its affiliated Massachusetts General Hospital and Brigham and Women's Hospital, as well as Johns Hopkins University School of Medicine and its hospital system. Clinicians at teaching hospitals fulfill three core roles: patient care, education, and research. Laboratories are often located adjacent to clinical wards to facilitate rapid translation of clinical questions into research projects. Beyond university systems, the U.S. also hosts a network of high-level independent research institutes—such as the Broad Institute, Salk Institute, and Cold Spring Harbor Laboratory—that focus on cutting-edge basic and translational research, operating with flexible mechanisms and high output. Additionally, the Department of Veterans Affairs (VA) hospital system maintains independent research programs.

2.1.3 Academic Evaluation: Papers, Grants, H-Index, and Peer Review

U.S. academic evaluation is characterized by intense competition and long assessment cycles. For physician-scientists, the most critical metric is not the total number of publications, but securing independent NIH funding. An R01 award signifies that a research proposal has passed the most rigorous peer review; thus, NIH funding itself serves as a talent filter. In terms of publications, emphasis is placed on journal prestige and actual citation impact. The H-index (the largest number H such that an author has H papers each cited at least H times) is widely used to measure sustained academic influence, though it has faced increasing criticism for favoring senior scholars and popular fields. Most universities operate a "up-or-out" tenure-track system: assistant professors who fail to achieve promotion to associate professor with tenure within six to eight years must leave. While this mechanism creates immense pressure and high attrition rates, it ensures a high overall standard among independent researchers.

2.1.4 Top Medical Journals and Academic Publishing Ecosystem

US-based or US-headquartered medical journals dominate global academic publishing. In 2024, The New England Journal of Medicine (NEJM) had an impact factor of 78.5; JAMA recorded 63.1; Nature Medicine reported 58.7; and foundational journals like Cell remain influential benchmarks. These publications enforce rigorous editorial screening, external peer review, and statistical verification. For clinical trial studies, they mandate prospective registration and adherence to reporting guidelines. Meanwhile, preprint platforms like bioRxiv and medRxiv have surged in recent years, enabling early dissemination before formal peer review. Open access (OA) adoption continues to rise, with public-funded research increasingly required to become freely available after an embargo period. Concurrently, the "paywalls" and high article processing charges imposed by major commercial publishers remain a source of ongoing controversy.

2.1.5 Physician-Scientist Training: MSTP and Dual-Track Integration Path

The United States has the most systematic physician-scientist training system, anchored by the Medical Scientist Training Program (MSTP). Established in 1964 with T32 funding from the NIH National Institute of General Medical Sciences, this program enables students to earn both a Doctor of Medicine (MD) and a Doctor of Philosophy (PhD) at the same university. The dual-degree track typically takes seven to eight years: students first complete medical coursework, then spend several years conducting doctoral research, before returning for clinical rotations. According to public data, in 2021, NIH-funded MSTPs included 53 programs directly supporting 1,132 dual-degree students under T32, complemented by other MD-PhD programs not receiving MSTP funding, forming a comprehensive two-track talent pipeline.

MSTP graduates can secure protected research time through the K-series career development awards after specialty training, then transition to independent faculty positions via mechanisms such as K99 or R00, and apply for R01. This pathway is tightly integrated. Although physician-scientists represent a small fraction of all physicians, they receive a disproportionately large share of NIH funding and serve as the core engine of medical innovation in the United States. The main challenges are the long training duration and high pressure. Recent budget fluctuations have further destabilized early-career researchers, making the "shrinking pipeline" of physician-scientists a persistent concern in the academic community.

2.1.6 Research Integrity Oversight: ORI and Institutional Accountability

Research integrity within the U.S. Public Health Service (PHS) system is overseen by the Office of Research Integrity (ORI), part of the Department of Health and Human Services. ORI defines research misconduct as fabrication, falsification, or plagiarism (FFP) in proposing, conducting, reviewing, or reporting research. Honest errors and differences in scientific judgment are not considered misconduct. Under 42 CFR Part 93, institutions receiving PHS funding bear primary responsibility for investigating and addressing misconduct. ORI provides oversight, review, and policy guidance, and may recommend findings and administrative actions to the Assistant Secretary for Health, such as debarment from federal grant programs for a specified period.

In subject protection, the U.S. established the Institutional Review Board (IRB) system to conduct pre-approval ethical reviews for human research under the Common Rule (45 CFR Part 46). The Office for Human Research Protections (OHRP) oversees policy enforcement, while drug and device trials are also regulated by the FDA. ORI's institutional accountability model, IRB pre-review requirements, and mandatory clinical trial registration work together to create a governance framework of "institutional self-regulation plus federal oversight." This system is not without flaws—significant misconduct cases have still emerged historically—but its design emphasizes procedural transparency and traceable penalties, making it worthy of thorough study.

2.2 UK Medical Academic System

2.2.1 Funding: NIHR, MRC, and Wellcome Trust

UK medical research funding is driven by a dual model of government and charity support, resulting in three core institutions. The first is the National Institute for Health and Care Research (NIHR), established in 2006 by the Department of Health (now the Department of Health and Social Care). As the primary funder of clinical and applied research in the UK, NIHR allocated approximately £1.638 billion in total expenditure during the 2024–2025 fiscal year. It funds Biomedical Research Centres (BRCs) and Applied Research Collaborations, operates the Clinical Research Network (CRN) nationwide to provide patient recruitment, sites, and staff support for trials within the NHS, and extensively supports clinical academic training. The second institution is the Medical Research Council (MRC), with origins dating back to 1913. Since 2018, it has been part of UK Research and Innovation (UKRI). With a core budget of approximately £602 million for the 2025–2026 fiscal year, MRC focuses on basic biomedical and methodological research.

Third is the Wellcome Trust, one of the world's largest medical charities. Fully funded by its own investment portfolio, it holds assets of approximately £38 billion. In 2024–2025, it spent £1.9 billion on grants across 133 countries, supporting over 2,700 active projects totaling around £7.3 billion, and funds the Wellcome Sanger Institute. Public funding targets clinical and national priorities, while charitable funds enable high-risk, long-term research. Together, these three sources complement each other, allowing the UK to maintain high research density despite its moderate economic size.

2.2.2 Academic Medical Center (AMC) Model

Academic Health Science Centres (AHSCs) serve as the primary organizational framework for integrating clinical care and research in the UK. Established through formal agreements between university medical schools and NHS Trust hospitals, AHSCs include leading institutions such as Oxford, Cambridge, University College London (UCL), and Imperial College London. Unlike integrated academic medical centers in the U.S., UK universities and NHS hospitals operate under separate legal employer frameworks. Physicians typically hold both honorary academic appointments at universities and clinical roles within the NHS, linked via "Honorary Contracts" that define their dual responsibilities. Within each AHSC, Academic Health Science Networks (AHSNs) are responsible for disseminating innovations to regional industries and community healthcare providers.

2.2.3 Clinical Academic Training Pathway

The UK offers Integrated Academic Training (IAT), a structured pathway for clinicians that runs parallel to specialty training, with clear progression and NIHR funding. It begins with the Academic Foundation Programme during the first two years of foundation training, introducing early research experience. Next, clinicians become Academic Clinical Fellows (ACF), spending 75% of their time in specialty training and 25% on research, primarily preparing for doctoral applications. Upon securing a doctoral research scholarship, they enter a full-time PhD program lasting three to four years. After graduation, they take up Clinical Lectureships (CL), dedicating roughly half their time to clinical duties and half to research, completing specialty certification while building postdoctoral achievements. The pathway culminates in advancement through senior fellowship programs to Senior Lecturer, Reader, or Professor. A key feature is that every step maintains clinical accreditation, allowing clinicians to pursue academic development without losing their professional career trajectory—preventing the gap where researchers fall behind in specialty qualifications after earning a doctorate.

2.2.4 REF Research Evaluation Framework

The Research Excellence Framework (REF) is a UK-specific, institution-level research assessment organized by higher education funding bodies approximately every six to seven years; the most recent was conducted in 2021. The REF 2021 evaluated 157 institutions across three components: outputs (60%), impact (25%), and environment (15%). Each submission received a rating from one to four stars, with four stars denoting "world-leading." Results showed that 41% of all submitted research achieved four stars and 43% reached three stars, while 36% of individual outputs were rated four stars. Unlike simple publication counts, the REF requires institutions to submit Impact Case Studies demonstrating how their research has concretely changed clinical practice, health policy, or industry through specific evidence. REF outcomes directly determine the amount of block research funding universities receive annually from the government and incentivize institutions to prioritize real-world contributions over mere publication volume. However, this system entails high assessment costs and creates opportunities for gaming the scoring system.

2.2.5 Medical Journals, Societies, and Integrity Governance

The UK hosts two top-tier global general medical journals: The Lancet, with a 2024 impact factor of 88.5 (ranking first in General & Internal Medicine), and The BMJ, with an impact factor of 42.7, which has long driven reforms in clinical evidence and research evaluation. In terms of professional societies, Royal Colleges—including the Royal College of Physicians and the Royal College of Surgeons—oversee specialty training and certification. The Academy of Medical Sciences represents academic excellence, while the British Medical Association (BMA) safeguards professional interests. Numerous specialty societies publish their own journals and guidelines. Regarding research integrity, the UK launched the Concordat to Support Research Integrity, requiring institutions to publish annual integrity statements. The UK Research Integrity Office (UKRIO) provides independent advisory support. Ethical review is coordinated centrally by Research Ethics Committees under the Health Research Authority (HRA), working within the NHS governance framework to establish a governance model characterized by industry concordats and institutional self-regulation.

2.3 German Medical Academic System

2.3.1 Funding Agencies: DFG and BMBF

The Deutsche Forschungsgemeinschaft (DFG) is Germany's largest university research funding agency. It operates under scientist self-governance, with review and decision-making bodies composed of representatives from universities and research institutions. According to its 2023 annual report, the DFG funded 31,750 projects totaling approximately €3.9 billion. Its funding instruments include individual research positions, project-based grants, coordination programs (such as Graduate Schools, Collaborative Research Centers, and Excellence Clusters), and major research equipment. The most prominent initiative in recent years is the "Excellence Strategy," implemented jointly by the federal and state governments. This strategy strengthens top-tier research and fosters collaboration between universities and external institutions through competitive selection of Excellence Clusters and Excellence Universities. The Federal Ministry of Education and Research (BMBF; renamed BMFTR following a 2025 institutional restructuring) represents the government in implementing strategic funding initiatives. In 2024, it allocated approximately €2.7 billion to "Health Research and Health Industry," prioritizing disease-oriented research centers, clinical research networks, and innovations in the biopharmaceutical sector.

2.3.2 Research system centered on university hospitals

In Germany, medical research is primarily conducted by approximately 33 university hospitals (Universitätsklinikum) and their affiliated medical schools. Similar to China's affiliated hospital system, German university hospitals simultaneously handle the most complex clinical care, medical education, and biomedical research, serving as the nation's primary hub for clinical studies. Their organizational structure centers on "chairs" (Lehrstuhl): each clinical department is led by a full professor (typically W3 level), who oversees clinical operations, personnel, and research direction. Beneath the professor are academic advisors, attending physicians, and researchers. Physicians at university hospitals hold dual roles as state civil servants and university academics, conducting both clinical work and research within the same institution. This model offers tight integration between clinical resources and research, along with strong departmental engineering capabilities; however, it also concentrates power heavily in the hands of full professors, which can slow the development of independence among junior scholars and maintain a rigid academic hierarchy.

2.3.3 Professoriate and Academic Promotion System

The traditional gateway to academic advancement in Germany is the "Habilitation," a high-level research achievement completed after earning a doctorate and independently by the scholar. It grants university teaching qualifications and has historically been a mandatory step for becoming a professor. Upon completing the Habilitation, scholars teach as "private lecturers" before securing a professorship through open recruitment. Germany's current salary system comprises three levels: W1 (Junior Professor), W2 (Regular Professor), and W3 (Chair Professor). Most professors hold tenured civil service positions. To prevent academic "inbreeding," the prevailing practice is to avoid promoting directly from within one's own institution; scholars must seek professorships at other universities, fostering cross-institutional exchange. In recent years, the Junior Professor program and Tenure Track systems have expanded, offering young scholars more predictable career paths than the traditional Habilitation. However, the Habilitation remains highly valued, particularly in the medical field.

2.3.4 National Research Institutions: Four Major Systems Including Max Planck and Helmholtz

Beyond universities, Germany has four major national research organizations that complement university hospitals. The Max Planck Society (MPG) focuses on basic research with over 80 institutes and is renowned for its biomedical work. The Helmholtz Association operates 18 large centers tackling big-science challenges like cancer, infectious diseases, and environmental health. The Leibniz Association bridges basic and applied research across more than 90 institutions. The Fraunhofer Society drives industrial applications. These organizations receive stable institutional funding from federal and state governments, complementing the competitive grants from DFG in a dual-track system of "stable support + merit-based selection." They are closely linked to universities and hospital networks through joint appointments, shared laboratories, and integrated collaborations.

2.3.5 Clinical Research Network and Translational Medicine

To translate strong basic research capabilities into clinical outcomes, Germany has systematically established the German Centre for Health Research (DZG) since 2009. It now comprises six centers: Neurodegenerative Diseases (DZNE), Infection (DZIF), Translational Cancer (DKTK), Cardiovascular (DZHK), Lung (DZL), and Diabetes (DZD). These centers network teams across university hospitals and institutes to share cohorts, biobanks, and data platforms. In methodological support, the Federal Ministry of Education and Research (BMBF) has funded the Clinical Trial Coordination Center Network (KKS) since 1999. With 18 centers today, it provides end-to-end services including study design, statistics, monitoring, data management, and quality assurance. Organizations like TMF coordinate efforts in data governance and biobank standards. Germany’s strengths lie in engineering rigor, standardization, and systemic integrity. Key challenges include high coordination costs across institutions and a conservative approach to digital health infrastructure.

2.4 Japanese Medical Academic System

2.4.1 Funding Programs: JSPS and AMED

Japan's medical research funding is primarily provided by two institutions. The Japan Society for the Promotion of Science (JSPS), an independent administrative agency, manages the Grant-in-Aid for Scientific Research (KAKENHI)—the country's most comprehensive competitive research fund supporting projects ranging from basic to applied research. In fiscal year 2026, total funding including KAKENHI reached approximately ¥301 billion. JSPS also offers doctoral and postdoctoral fellowships, serving as a key funding source for early-career researchers. Established in 2015, the Japan Agency for Medical Research and Development (AMED) consolidates previously fragmented medical R&D funds from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, and the Ministry of Economy, Trade and Industry, following the NIH model. AMED's annual budget for fiscal year 2025 was ¥123.2 billion, supplemented by ¥17.5 billion in adjustment funds. Projects are managed through an integrated Program Officer system covering the full spectrum from basic and clinical research to drug/device development and commercialization. In 2024, the average project approval rate was approximately 21.5%.

2.4.2 University School of Medicine and National Center for Global Health and Medicine

The core of Japan's medical education and research lies in the medical schools of national, public, and private universities. The undergraduate program spans six years and traditionally follows a "chair system," where professor-led chairs integrate teaching, research, and clinical duties—mirroring Germany's chair structure—with university-affiliated hospitals serving as the primary sites for clinical research. Outside the university system, the Ministry of Health, Labour and Welfare operates six national specialized medical research centers focused on cancer, cardiovascular disease, mental health and neurology, pediatrics, international medicine, and longevity care. Among these, the National Center for Global Health and Medicine (NCGM) combines research, clinical practice, and international collaboration, standing as Japan's flagship institution for global health and infectious disease response. Around 2015, these centers transitioned to independent administrative法人 status, offering greater operational flexibility than traditional universities.

2.4.3 Physician-Researcher Training Pathway

In Japan, the primary pathway to becoming a physician-researcher involves completing a six-year undergraduate medical program and obtaining a medical license, followed by two years of initial clinical training. Physicians then enroll in a four-year doctoral program at a graduate school to earn a Ph.D., during which they may apply for JSPS doctoral scholarships to secure independent research funding. After graduation, they typically remain in university departments as assistants or lecturers, gain broader experience through postdoctoral training abroad, and gradually advance to associate professor or full professor roles. To address the shortage of clinical research talent, Japan has established the "Certified Clinical Research Physician" and "Clinical Research Supervising Physician" systems under the Clinical Research Act, requiring physicians to complete systematic training in ethics and methodology and practice within registered institutions. AMED also offers dedicated training programs for physician-researchers. Japan continues to face challenges such as young physicians' disengagement from research, declining doctoral enrollment rates, and excessive working hours. The physician working hour regulations implemented in 2024 aim to balance adequate rest with protected time for research activities.

2.4.4 Medical Society and Specialized Journal System

Japan's medical society ecosystem is highly developed. The Japanese Medical Association (JMA) comprises over 130 specialized divisions covering virtually all basic and clinical disciplines. The Japan Federation of Medical Associations unites 142 medical academic organizations, representing the profession and coordinating specialist training. Since 2018, specialist certification has been centrally managed by the Japan Board of Specialized Medicine (JBSM), a third-party body overseeing 19 core clinical fields, replacing the previous system where individual societies handled their own certifications. Most societies publish official journals, creating an extensive network of specialty publications. Articles are typically published in Japanese or English; historically, journals like *Nihon Igai Shinpo* have exerted significant influence among practicing physicians. While Japanese researchers increasingly publish in international journals as globalization advances, society-affiliated journals remain vital platforms for domestic academic exchange and continuing medical education.

2.4.5 Clinical Research Advancement and Ethical Oversight

Japan's most significant institutional development in recent years is the Clinical Research Act, implemented in 2018. This law defines research using pharmaceuticals and medical devices to verify their efficacy and safety as "Specific Clinical Research." It requires such studies to undergo review by a Designated Committee approved by the Ministry of Health, Labour and Welfare (MHLW), register on the Japan Registry of Clinical Trials (jRCT), and adhere to strict regulations regarding the Principal Investigator, corporate funding disclosure, and conflicts of interest—establishing the "Designated Clinical Research Physician" system. On the ethics front, Japan consolidated three previously separate ethical guidelines into the "Ethical Guidelines for Life Sciences and Medical Research Involving Human Beings" in 2021. Issued jointly by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), MHLW, and AMED, this integration aligns with the Clinical Research Act. Drug and device development reviews are managed by the Pharmaceuticals and Medical Devices Agency (PMDA). Overall, Japan has strengthened research transparency through legislation and a centralized registration platform, achieving leading levels of regulatory precision in Asia. However, challenges remain, including rising compliance costs and some constraints on investigator-initiated trials.

2.5 Australian Medical Academic System

2.5.1 NHMRC Funding Framework and MRFF Innovation

The National Health and Medical Research Council (NHMRC) is Australia's statutory federal funding body, established in 1936. It oversees research grants, ethical standards, and clinical guidelines. Its streamlined funding program includes: - **Ideas Grants**: Support for innovative research concepts. - **Synergy Grants**: Fund multidisciplinary teams tackling problems beyond the scope of a single researcher. - **Investigator Grants**: Provide salary plus research support to top researchers at all career stages, categorized into five levels: Emerging Leadership (EL1, EL2) and Leadership (L1, L2, L3). - **Centres of Research Excellence (CRE)**: Foster collaborative research and develop future talent. All applications undergo rigorous peer review by domestic and international experts. The process prioritizes "equity of opportunity," accounting for the circumstances of women, caregivers, and early-career researchers.

In 2015, Australia established the Medical Research Future Fund (MRFF), a sovereign-style medical research fund uniquely backed by A$20 billion in federal capital and sustained through investment returns. Together, NHMRC and MRFF provide approximately A$1.5 billion annually. The MRFF's third decade plan (FY2024–FY2034) allocates A$6.5 billion with a stronger focus on mission-oriented research and clinical translation. While NHMRC prioritizes free exploration, MRFF targets strategic needs, enabling Australia to maintain high research efficiency despite modest R&D intensity of around 1.86% in 2021.

Collaboration between 2.5.2 medical research institutions and universities

A hallmark of Australian medical research is the dual strength of universities and independent medical institutes. The medical schools and affiliated hospitals of the Group of Eight (Go8) lead major teaching and clinical research, including those at the University of Sydney, the University of Melbourne, and Monash University. Alongside them are world-renowned independent institutes such as the Walter and Eliza Hall Institute (WEHI), Garvan Institute of Medical Research, Baker Heart and Diabetes Institute, QIMR Berghofer Medical Research Institute, and Harry Perkins Institute. Most of these institutes are non-profit entities that collaborate with nearby universities and hospitals through joint appointments and training programs, supported by state governments and charitable donations. The Commonwealth Scientific and Industrial Research Organisation (CSIRO) provides national-level support in data science, digital health, and preventive research. Robust competition and mature collaboration among diverse stakeholders are key strengths of Australia's system.

2.5.3 Clinical Investigator Training Path

In Australia, academic development for clinicians typically runs parallel to specialty training through institutions like the Royal Australasian College of Physicians (RACP). After completing basic training, physicians can transition to full-time doctoral programs by applying for Emerging Leader grants from the National Health and Medical Research Council (NHMRC), PhD positions within Cooperative Research Centres (CRCs), or various charitable scholarships. Upon completion, they return to clinical practice while pursuing postdoctoral funding. The NHMRC's Early and Mid-Career Researcher (EMCR) policy mandates that projects reserve slots for early-career scholars and assess their CVs based on relative opportunity during review. National Clinical Research Networks and state-level clinical translation hubs—such as those in Sydney, Melbourne, and Brisbane—provide support with study design, statistics, and trial coordination. While this pathway is less standardized than the UK's IAT system, it offers diverse funding options and flexible institutional choices, allowing clinician-researchers to balance clinical and research responsibilities at their own pace.

2.5.4 ERA Research Evaluation and Ethics Standards

The Excellence in Research for Australia (ERA), organized by the Australian Research Council (ARC), was conducted in 2010, 2012, 2015, and 2018. It evaluated university research across disciplines on a five-point scale, with Level 5 indicating "well above world standard." In the 2018 assessment, 40% of the participating Level 4 units received a Level 5 rating. The planned 2023 ERA cycle was ultimately not implemented; instead, the government developed a new framework for assessing research quality and impact to reduce reliance on bibliometrics and emphasize contributions. This shift aligns with trends seen in the UK's Research Excellence Framework (REF) and global movements toward responsible research evaluation. On ethics, the National Statement on Ethical Conduct in Human Research, published by the National Health and Medical Research Council (NHMRC) and maintained by the Australian Health Ethics Committee (AHEC), serves as the national standard. Institutional Human Research Ethics Committees (HRECs) use it for pre-approval reviews, establishing unified ethical guidelines and review criteria nationwide.

2.6 Dutch Medical Academic System

2.6.1 ZonMw and other medical research grants

The Netherlands Organisation for Health Research and Development (ZonMw) is the central funding body for medical research in the Netherlands. Established in 1998, it operates as an independent executive agency under the Ministry of Health, Welfare and Sport (VWS) and also manages the health portfolio for the Netherlands Organisation for Scientific Research (NWO). ZonMw functions through a model combining program planning and peer review. Its funding supports both curiosity-driven research and applied projects focused on healthcare policy, appropriate care, long-term care, and primary care. For example, the "Appropriate Care Framework Program" (2024–2028) has a budget of €290 million, while the fourth phase of the Medicines Assessment Project (GGG) is allocated €83.1 million. Early-career researchers receive support through NWO's Veni, Vidi, and Vici grant schemes, which represent the three tiers of academic progression in the Netherlands. ZonMw also actively participates in EU joint initiatives and the "Health~Holland" innovation alliance to foster collaboration between research, policy, and industry.

2.6.2 University Medical Center (UMC) Model

Medical research in the Netherlands is concentrated almost entirely within university medical centers (Universitair Medisch Centrum, UMC). Following the merger of Amsterdam AMC and VUmc, the Federation of Dutch University Medical Centers (NFU) now comprises seven members: Amsterdam UMC, Erasmus MC Rotterdam, UMC Utrecht, Leiden LUMC, UMCG Groningen, Radboudumc Nijmegen, and Maastricht UMC+. Each UMC integrates its medical school, hospital, and research institute under a single legal entity, enabling physicians, researchers, and students to work within one organization. This represents one of Europe's most integrated models for clinical care, education, and research. Most UMCs also host methodological, epidemiological, and biostatistical centers—such as the Julius Center at UMC Utrecht—providing robust methodological support for clinical studies. These institutions have helped establish the Netherlands as a key birthplace of evidence-based medicine and the Cochrane Collaboration.

2.6.3 High-Quality Clinical Research Tradition

The Netherlands has achieved world-class clinical research despite its small size, distinguished by large pragmatic trials, registry-based real-world studies, and primary care research. Leveraging its robust general practitioner system and electronic health records, the country has built high-quality cohorts for common diseases, chronic disease management, and end-of-life care. Study designs prioritize questions that truly matter to patients rather than relying solely on laboratory surrogate endpoints. ZonMw provides long-term funding through a dedicated "Large Trials" program for multicenter studies. The Netherlands boasts strong expertise in clinical epidemiology, trial methodology, and systematic reviews, maintains an open-science mindset, and actively promotes data sharing, protocol preregistration, and transparent reporting—establishing a reputation for being "small but precise with methodological rigor."

2.6.4 Medical Ethics and Registration System

Ethical governance in the Netherlands centers on the Central Committee on Research Involving Human Subjects (CCMO). Established in 1999, the CCMO enforces the Medical Research Involving Human Subjects Act (WMO) and the Embryo Act, while overseeing accredited Medical Ethics Review Committees (METCs). Studies falling under the WMO must obtain a positive opinion from either an METC or the CCMO before commencing. The committee evaluates participant burden, informed consent, data protection, and scientific quality. Regarding trial registration, the Netherlands Trial Register (NTR) serves as a primary registry for the WHO International Clinical Trials Registry Platform. The Netherlands has a strong tradition of prospective registration and public results dissemination and was an early adopter of international clinical trial registration standards. Following the implementation of the EU Clinical Trials Regulation (CTR), the CCMO acts as the Dutch Competent Authority, serving as the single point of contact for the EU portal. Rigorous ethical review and registration systems form the foundation of the long-standing high credibility of medical research in the Netherlands.

Chapter 3: Overview of the Chinese Medical Academic System

3.1 Research Funding System

China's medical research funding landscape is now characterized by a primary channel of the National Natural Science Foundation of China (NSFC), anchored by major science and technology projects, with supplementary support from industry and local funds. The NSFC serves as the core funder for basic research, offering various grant types including General Programs, Youth Science Fund, Key Projects, Regional Science Funds, Excellent Young Scientists Fund (Youqing), and Distinguished Young Scholars Fund (Jieqing). In 2024, the NSFC funded approximately 54,900 projects, comprising 20,758 General Programs, 23,226 Youth Projects, 433 Jieqing grants, and 654 Youqing grants. Taking the Department of Medical Sciences as an example, in 2024, it received 48,854 applications for the Youth Science Fund and funded 5,616 projects, resulting in an average funding rate of 11.50% and an average award strength of 300,000 RMB per project. The Regional Science Fund achieved a funding rate of 10.31%. Additionally, special programs were established for "Exploratory Research on Scientific Problems Originating from Clinical Practice" and a "Clinical Special Program," with the latter offering an average award strength of 660,000 RMB per project, explicitly encouraging clinicians to derive scientific questions from real-world clinical practice.

The Ministry of Science and Technology supports strategic, cluster-based research in chronic disease prevention, precision medicine, new drug development, and infectious disease control through the National Key R&D Program and major projects under "Innovation 2030," emphasizing full-chain organization and technology transfer. The National Health Commission funds clinical evaluations, health standards, and public health policy research via sector-specific grants. Provincial and municipal governments also provide local natural science funds and medical technology projects. In recent years, corporate investment and social donations have grown rapidly. Compared to the NIH's researcher-driven model, China's funding system places greater emphasis on top-level planning and mission-oriented projects, offering strong organizational mobilization capabilities. However, there is room for improvement in per-capita funding intensity and stable support mechanisms for free exploration projects.

3.2 Research Entities: Medical Universities, Affiliated Hospitals, and National Institutes

In China, the core of medical research lies in medical universities (or medical schools within comprehensive universities) and their affiliated hospitals. These affiliated hospitals integrate clinical care, teaching, research, and standardized training. Leveraging a vast patient base, they hold significant advantages in clinical data and sample resources; most National Natural Science Foundation of China (NSFC) projects in medicine are undertaken by these institutions. At the national level, the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) operate as a single entity, serving as the central hub for national medical research and high-level talent development. The Academy of Military Medical Sciences excels in emergency medicine and drug development. Institutes under the Chinese Academy of Sciences focus on fundamental life science research, while the China Academy of Chinese Medical Sciences leads TCM research. Additionally, the government has established 50 National Clinical Research Centers covering major disease areas, creating a collaborative network with grassroots medical institutions. Overall, China's medical research ecosystem is dominated by public institutions with immense clinical resources, though cross-institutional data sharing and the development of clinical research units continue to deepen.

3.3 Academic Evaluation System

For years, evaluations of Chinese medical institutions have centered on four key areas: publications, research projects, awards, and professional title reviews. Over-reliance on journal tier, impact factor, and SCI indexing led to excessive quantification, fueling the "publish-or-perish" culture and even spawning "paper mill" operations. In response, national reforms have been steadily implemented: since 2018, policies have sought to eliminate overemphasis on titles, degrees, papers, and awards; in 2020, measures were introduced to devalue "SCI supremacy"; and in 2022, the Ministry of Science and Technology launched pilot programs for reforming scientific talent evaluation, introducing categorized assessment, representative work review, long-cycle evaluation, and peer review. These reforms recognize that clinicians' contributions may include high-quality papers, clinical guidelines, treatment protocols, real-world evidence, or technological innovations. Title reviews are increasingly prioritizing clinical performance and frontline grassroots practice. While this direction aligns with international principles like the San Francisco Declaration on Research Assessment (DORA), the development of specific new standards and building trust in peer review remain ongoing challenges.

3.4 Medical Journals and Academic Societies

The Chinese Medical Association (CMA) is the core organization of China's medical academic community. It publishes over 190 journals in the "Zhonghua" series. The flagship journal, *Chinese Medical Journal* (CMJ), was founded in 1915 and is one of the oldest and most authoritative medical journals in China. The English edition, *Chinese Medical Journal* (CMJ), was established in 1887 as China's longest-running medical journal. Indexed by multiple international databases, CMJ achieved an impact factor of 7.5 in 2023 and ranks in JCR Q1. In recent years, high-impact Chinese journals have risen rapidly. Titles such as *Signal Transduction and Targeted Therapy* (STTT), *Cell Research*, and *Cell Discovery* are now among the world's most-cited journals. STTT reached an impact factor of 39.3 in 2023. The government supports flagship journals through the "China Excellence in Science and Technology Journals Action Plan." Under the CMA, there are nearly 90 specialized societies. The Chinese Medical Association manages physician practice standards and residency training. These societies also organize academic conferences, develop clinical guidelines, and provide continuing education. Compared to the four major international publishers, Chinese journals still need time to build global influence and attract high-quality submissions.

3.5 Medical Research Talent Development

China's medical talent development integrates degree programs, standardized residency training, and continuing education. At the graduate level, degrees are categorized as academic or professional; clinical medicine master's programs typically align with residency training, enabling students to complete coursework, rotations, and thesis requirements within three years. Academic master's and doctoral programs emphasize research training. The postdoctoral system provides a transitional period for independent research for PhD graduates, with funding scales expanding in recent years. High-level talent is supported through tiered national and local initiatives—including the National Distinguished Young Scholars Program, Excellent Young Scientists Program, Ministry of Education's Changjiang Scholars Program, National Talent Support Plan ("Ten Thousand Talents Plan"), and regional projects—forming a multi-tiered "talent title" system. While this framework has objectively stimulated research output, it has also led to title competition and redundant recognition; ongoing efforts focus on optimization and consolidation. Compared to the U.S. MSTP model, China lacks large-scale standardized MD-PhD integrated programs. Systemic integration of dual-track training remains under exploration, though some universities have piloted "clinical scientist" tracks and eight-year research-intensive pathways.

3.6 Clinical Research and Translational Medicine Development

Over the past decade, China has witnessed the most rapid development of its clinical research infrastructure. National clinical research centers, research wards, and translational medicine centers have been established sequentially. Drug trial institutions have shifted from a qualification-based system to a filing management model, while pre-trial reviews and process supervision have become increasingly standardized. The Chinese Clinical Trial Registry (ChiCTR) and the National Drug Clinical Trial Registration and Information Disclosure Platform are now the primary channels for study registration, significantly enhancing transparency. The 2023 "Measures for Ethical Review of Life Sciences and Medical Research Involving Humans" unified ethical review requirements, and the "Regulations on the Administration of Human Genetic Resources" along with their implementing rules have standardized the collection, storage, and external provision of samples and data. In terms of output, according to WHO's International Clinical Trials Registry Platform, China registered more new clinical trials in 2024 than the United States. Innovative drug trials increased from 163 in 2015 to 1,806 in 2024, approaching the U.S. figure of 1,669. While China is rapidly catching up in the "quantity" of trials, it still lags behind in leading multi-center international trials, original study design, and contributions to clinical guidelines.

3.7 Research Integrity and Ethics Oversight

China has adopted a governance approach of "zero tolerance and strong supervision" for research integrity. In 2022, the Ministry of Science and Technology and other departments jointly issued the "Rules for Investigating and Handling Research Misconduct" (Guo Ke Fa Jian [ 2022 ] No. 221), which standardized the definition of misconduct, investigation procedures, and disciplinary measures. The National Health Commission has publicly reported multiple batches of cases involving "paper mills," revoking professional titles, canceling projects, and restricting future applications for those involved. The National Committee on Science and Technology Ethics was established in 2019 to coordinate ethical governance across science and technology. In 2023, the Ministry of Science and Technology and other departments issued the "Interim Measures for Scientific and Technological Ethics Review," which, together with medical ethics review regulations, forms a comprehensive review system covering human subjects, experimental animals, and emerging technologies. Most medical institutions have established offices for research integrity and ethics committees. Overall, China's institutional framework is largely complete with strong regulatory enforcement; the next focus should be on reinforcing institutional accountability, fostering a culture of integrity, and enhancing the professional independence of ethics reviews.

Chapter 4: Comparative Analysis of Chinese and Foreign Medical Academic Systems

Comparison of Research Funding Strength and Mechanisms for 4.1

In terms of total funding, the U.S. NIH's annual budget is approximately $47 billion; combined with other federal and philanthropic funds, it forms the world's largest biomedical research portfolio. China's total R&D investment has reached the level of 3.6 trillion yuan, but there remains a gap in per-capita intensity and stability for basic medical research. In terms of mechanisms, the U.S. and Europe generally rely on investigator-initiated proposals, two-tier peer review, and high competition, with success rates typically ranging from just over 10% to slightly above 20%. China has been steadily improving its peer review system in recent years, with a higher proportion of mission-oriented projects and strong capabilities in organizing major collaborative攻关 efforts.

Table 4-1: Comparison of Research Funding Strength and Mechanisms

Comparison of 4.2 Research Institution Organizational Models

Institutional models for medical research and education generally fall into two categories: university-affiliated and independent institutes, with most organizations today operating as a hybrid. In the United States, Germany, and China, university hospitals form the core alongside powerful independent institutes. The Netherlands' University Medical Centers (UMCs) integrate clinical care, research, and teaching under a single legal entity, achieving the highest level of integration. In the UK, collaboration is achieved through dual-employer honorary contracts between universities and NHS trusts.

Comparison of Research Institution Organizational Models: Table 4-2

4.3 Comparison of Academic Evaluation Orientations

Global trends in evaluation systems are shifting from counting quantity to assessing quality and impact. The UK's REF is known for its impact case studies and star profiles; Australia's ERA uses a tiered system and is designing a new framework; the US relies on NIH funding and tenure reviews for substantive screening; China is driving a similar transformation through "breaking the five onlys" and representative work policies. A shared challenge is establishing truly credible and accountable peer review.

Table 4-3: Comparison of Academic Evaluation Orientations

Comparison of 4.4 Physician-Scientist Training Programs

The U.S. MSTP program, with its dual-degree structure and K award pathway, is the most mature model. The U.K.'s IAT integrates research training into specialty training, ensuring continuous clinical accreditation at every step. These two represent distinct paradigms of dual-track integration. Japan and Germany follow traditional, rigorous pathways, while Australia and the Netherlands provide flexible support through talent funding. China has implemented residency integration and pilot eight-year programs, but a fully integrated, standardized clinical scientist pathway remains incomplete.

Table 4-4: Comparison of Physician-Scientist Training Programs

Comparison of international influence among 4.5 medical journals

In 2024, the impact factors of the four major general medical journals were: The Lancet (88.5), NEJM (78.5), JAMA (63.1), and BMJ (42.7). The UK and US dominate this top-tier group. Chinese journals such as STTT and Cell Research have entered the high-impact tier, and CMJ remains in JCR Q1. However, global influence and access to high-quality submissions for flagship general medicine journals still largely reside with Western publishers. Importantly, impact factor is an average metric at the journal level and should not be equated with the quality of individual articles.

Table 4-5: Comparison of International Influence Among Medical Journals

4.6 Clinical Research Capability and Output Comparison

China's annual clinical trial registrations now rank among the highest globally, with cell therapy and other areas approaching U.S. levels, reflecting dual benefits from patient resources and policy support. However, the U.S., UK, and Netherlands still maintain clear advantages in leading international multicenter trials, original study design, authorship of top-tier guidelines, and methodological innovation. The current reality is "leading in volume while catching up in quality."

Table 4-6: Clinical Research Capability and Output Comparison

Comparison of 4.7 Research Integrity Governance Systems

The U.S. ORI centers on FFP definitions and institutional accountability; the UK relies on integrity covenants and annual institutional self-declarations; Germany and Japan leverage academic autonomy alongside legislative oversight. China enforces uniform rules via Document 221 and issues multi-batch alerts against "paper mills," resulting in the strongest regulatory rigidity. The common global direction is proactive prevention, process transparency, and traceable penalties; differences stem primarily from traditions of institutional autonomy and the degree of government intervention.

Comparison of Research Integrity Governance Systems for Table 4-7

Comparison of 4.8 Translational Medicine and Industry-Academia-Research Collaboration

The U.S. leads with the most mature industry-academia-research ecosystem, driven by venture capital, biotech clusters, and NIH SBIR programs. Germany relies on Fraunhofer institutes and "hidden champion" companies for steady commercialization. The Netherlands and Australia leverage innovation alliances and translation centers to coordinate collaboration. In China, policy-driven expansion of translation centers and industrial funds has significantly boosted patent and new drug output, though the efficiency of translating original discoveries into clinical products and the early-stage investment ecosystem still need cultivation.

Table 4-8: Comparative Analysis of Translational Medicine and Industry-Academia-Research Integration

Chapter 5: Implications for Primary Care Physicians

Reference Pathways for Grassroots Physicians to Conduct Clinical Research

The greatest advantage for primary care physicians conducting research isn't lab resources—it's proximity to real patients. Start with clinical evidence and build upward, rather than diving straight into complex mechanistic studies. Level 1: Case reports and case series documenting rare presentations, unexpected efficacy, or adverse drug reactions, following CARE guidelines. Level 2: Quality improvement projects addressing specific departmental issues (e.g., antibiotic use, hospital workflow, chronic disease follow-up rates) using the Plan-Do-Check-Act cycle. Level 3: Cross-sectional surveys and retrospective cohort studies leveraging existing medical records, lab results, and follow-up data to answer clinical questions, adhering to STROBE guidelines. Level 4: Prospective cohorts, registry studies, and randomized controlled trials, following CONSORT guidelines with pre-registration.

Follow three key principles when selecting research topics: first, address "real problems" arising from recurring clinical challenges rather than chasing trends; second, ensure feasibility in terms of sample size, data availability, and ethical approval within your institution's capacity; third, maintain compliance—human-subject studies must obtain ethics approval and register in advance on platforms like ChiCTR if required, while strictly managing human genetic resources and patient privacy. In practice, actively seek support from your department and hospital, collaborate with university or tertiary care teams to leverage their methodological, statistical, and ethical expertise, and consider joining multicenter studies as a co-author during the early stages to gain experience before leading independent proposals. For funding, start with municipal, institutional, or industry-specific grants, build preliminary data, and then pursue provincial or National Natural Science Foundation projects. Your grassroots experience and real-world data can serve as distinctive competitive advantages.

5.2 Channels for International Academic Exchange and Cooperation

International academic exchange is not limited to studying abroad; primary care physicians can build a multi-channel strategy. Start by leveraging free, high-quality public resources: search PubMed/PMC for literature, access systematic reviews via the Cochrane Library, and track ongoing trials through ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Next, join international specialty societies as a young member or international affiliate to receive newsletters and webinars at low cost, keeping you updated on cutting-edge developments. Online platforms also offer open courses in research methods, evidence-based medicine, and research ethics.

After achieving initial results, submit abstracts to international conferences for poster or oral presentations. This is a cost-effective way to gain peer feedback and build connections. Next, apply for short-term visiting scholar positions or joint training programs; many provinces and hospitals in China offer dedicated funding. International research collaborations should be formalized through official agreements signed by your institution, clearly defining data ownership, authorship rules, and mutual recognition of ethics standards to avoid compliance risks associated with informal individual arrangements. For opportunities along the "Belt and Road," consider conducting joint research tailored to regional disease patterns—a proactive direction where Chinese physicians can help shape global collaboration frameworks.

Methods to Integrate 5.3 Research Thinking into Clinical Practice

Research thinking is not mysterious; it centers on the habit of "ask—verify—validate—reflect." When making clinical decisions, practice breaking down questions using the PICO framework: Population, Intervention, Comparison, and Outcome. Then, retrieve literature with structured queries to assess evidence levels and applicability, rather than relying on experience or memory. While reading studies, maintain a critical mindset: focus on study design, sample sources, bias control, and conflicts of interest. Remember that statistical significance does not equal clinical importance, and surrogate endpoints do not necessarily translate to patient benefit.

In daily practice, standardized documentation of medical records, follow-ups, and adverse events builds data for future real-world studies. For complex cases, cultivate the habit of researching literature, creating case files, and maintaining regular follow-ups; a single well-documented long-term follow-up can become valuable research material. Additionally, establish a personal knowledge management system to continuously archive clinical questions, literature notes, and data dictionaries. Over years, clinical expertise and research capabilities reinforce each other: research enhances clinical precision, while clinical experience grounds research—this synergy defines the unique appeal of the physician-scientist career.

5.4's Observations on the Reform of China's Medical Academic System

Drawing on global experience and domestic practice, we can identify three key directions for reforming China's medical academic system. First, evaluation criteria will continue to shift from "quantity" to "value." The emphasis on representative works, differentiated assessment models, and clinical performance will intensify, narrowing the space for chasing impact factors alone—a positive development for clinicians focused on patient care and practical work. Second, the construction of clinical research systems remains in a growth phase. Improvements in national clinical research centers, specialized research wards, registration platforms, and ethical guidelines will continue to reduce institutional costs for physicians conducting rigorous studies. Third, oversight of research integrity will remain stringent long-term. The operating margins for paper mills and ghostwriting services will be further compressed, with institutional accountability and full-process traceability becoming standard practice.

Fourth, open science and data-driven research are inevitable trends. Data sharing, pre-registration, open access, and AI-assisted research tools will reshape the research workflow; clinicians who proactively master methodology will reap exceptional returns. Fifth, China's unique advantages—its vast patient population, strong organizational mobilization capacity, and rapid industry adoption—are translating into tangible clinical research outputs. However, addressing gaps in original thinking, methodological expertise, and global influence requires patience; this cannot be achieved overnight. For frontline clinicians, the priority is not to worry about systemic differences but to deepen, standardize, and sustain their work on concrete clinical questions within an evolving institutional framework. Ultimately, grand academic systems are built from such specific, solid contributions.

References

[1] NIH. Historical Budget Information (Appropriations). https://www.nih.gov/about-nih/what-we-do/nih-almanac/appropriations-section-1

[2] NIH Office of Budget. Overall Appropriations Tables. https://officeofbudget.od.nih.gov/

[3] World Bank. Research and Development Expenditure (% of GDP). https://data.worldbank.org/indicator/GB.XPD.RSDV.GD.ZS

[4] NCSES/NSF. The State of U.S. Science and Engineering 2026. https://ncses.nsf.gov/pubs/nsbsep20261/figure/25

[5] National Natural Science Foundation of China. 2024 Funding Summary. https://www.nsfc.gov.cn/

[6] National Bureau of Statistics. Statistical Bulletin on National Science and Technology Funding in 2024. https://www.stats.gov.cn/sj/zxfb/202509/t20250929_1961429.html

[7] Government of the People's Republic of China. Statistical Bulletin on National Economic and Social Development for 2024. https://www.gov.cn/lianbo/bumen/202502/content_7008605.htm

[8] NIHR. Annual Report 2024/25, Financial Summary. https://www.nihr.ac.uk/about-us/who-we-are/reports-and-performance/annual-report-202425/financial-summary

[9] UKRI Corporate Plan Update 2025 to 2027. https://www.ukri.org/

[10] Welcome. Annual Report and Financial Statements 2024/25. https://wellcome.org/insights/articles/wellcome-annual-report-and-financial-statements-202425

[11] DFG. Annual Meeting 2024 Press Release No. 28. https://www.dfg.de/en/service/press/press-releases/2024/press-release-no-28

[12] BMFTR Data Portal. Science and Research Expenditure by Funding Area. https://www.datenportal.bmftr.bund.de/

[13] AMED. Agency Profile and Budget FY025. https://www.amed.go.jp/content/000150765.pdf

[14] JSPS: Organization and Budget. https://www.jsps.go.jp/english/e-organization/budget/

[15] Australian Government Department of Health. Transforming Health and Medical Research. https://www.health.gov.au/

[16] Australian Research Council. Excellence in Research for Australia. http://www.arc.gov.au/excellence-research-australia

[17] CCMO. About the Central Committee on Research Involving Human Subjects. https://english.ccmo.nl/about-ccmo

[18] GlobalData: Global Clinical Trial Landscape Factsheet. https://www.globaldata.com/health-economics/pharmatrends/contribution-to-clinical-trials-worldwide.pdf

[19] Clarivate. Journal Citation Reports and Research Integrity Updates. https://clarivate.com/

[20] National Health Commission of the People's Republic of China. Rules for Investigation and Handling of Research Misconduct (Guo Ke Fa Jian [ 2022 ] No. 221). https://www.nhc.gov.cn/

[21] Government of China. Measures for the Ethical Review of Life Science and Medical Research Involving Humans. https://www.gov.cn/zhengce/zhengceku/2023-02/28/content_5743658.htm